Sernova Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jonathan M. Rigby

Algemeen directeur

CA$3.4m

Totale compensatie

Percentage CEO-salaris	6.1%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Feb 23

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Aug 11

Analyse CEO-vergoeding

Hoe is Jonathan M. Rigby's beloning veranderd ten opzichte van Sernova's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Oct 31 2024	CA$3m	CA$211k	-CA$32m

Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Jonathan M. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 163.68K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Jonathan M. te vergelijken met de prestaties van het bedrijf.

CEO

Jonathan M. Rigby (56 yo)

less than a year

Tenure

CA$3,432,127

Compensatie

Mr. Jonathan M. N. Rigby, M.B.A., has been Executive Chairman of Sernova Corp. since July 15, 2024 and serves as its Director since May 28, 2024 and CEO since August 2024. He is Chairman and Chief Business...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan M. Rigby	Executive Chairman & CEO	less than a year	CA$3.43m	geen gegevens
James Parsons	CFO & Director	less than a year	CA$1.38m	0.12% CA$ 84.6k
Frank Shannon	Senior VP of Clinical Development and Regulatory Affairs	less than a year	CA$335.83k	geen gegevens
Modestus Obochi	Chief Business Officer	1.3yrs	CA$499.49k	0.015% CA$ 11.0k
David Burke	Vice President of Investor Relations	less than a year	geen gegevens	geen gegevens
Marylyn Rigby	Chief Communications Officer	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van SVA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan M. Rigby	Executive Chairman & CEO	less than a year	CA$3.43m	geen gegevens
James Parsons	CFO & Director	12.7yrs	CA$1.38m	0.12% CA$ 84.6k
Norman C. Wong	Member of Scientific Advisory Board	18.4yrs	geen gegevens	geen gegevens
Jannette Dufour	Member of Scientific Advisory Board	18.3yrs	geen gegevens	geen gegevens
George King	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Clive Patience	Member of Scientific Advisory Board	18yrs	geen gegevens	geen gegevens
Steven Paraskevas	Member of Scientific Advisory Board	14yrs	geen gegevens	geen gegevens
Bernd Muehlenweg	Director	less than a year	CA$114.00k	geen gegevens
David Lillicrap	Member of Scientific Advisory Board	5.9yrs	geen gegevens	geen gegevens
Anke Schulte	Member of Global Advisory Board	4.4yrs	geen gegevens	geen gegevens
Stephen Sangha	Independent Director	1.7yrs	CA$126.89k	4.01% CA$ 2.9m
Sam Wiseman	Member of Scientific Advisory Board	3.7yrs	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/24 16:26
Aandelenkoers aan het einde van de dag	2024/12/24 00:00
Inkomsten	2024/10/31
Jaarlijkse inkomsten	2024/10/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Sernova Corp. wordt gevolgd door 8 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Christian Orquera	First Berlin Equity Research GmbH
Joseph Pantginis	H.C. Wainwright & Co.
Chelsea Stellick	iA Capital Markets

Sernova Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Independent Director recently sold CA$223k worth of stock

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Recent updates

New minor risk - Financial position

New minor risk - Profitability

Forecast to breakeven in 2027

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Price target decreased by 18% to CA$2.88

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold CA$223k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Price target decreased by 14% to CA$3.52

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New minor risk - Share price stability

New minor risk - Market cap size

Price target decreased by 13% to CA$3.53

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Price target decreased by 16% to CA$3.52

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Price target increased to CA$4.21

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Executive Chairman of the Board recently bought CA$65k worth of stock

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought CA$78k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Independent Chairman exercised options to buy CA$272k worth of stock.

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

New 90-day high: CA$0.75

New 90-day high: CA$0.57

New 90-day high: CA$0.31

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

New 90-day low: CA$0.26

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding